Luye Pharma
Luye Pharma Group Ltd., commonly referred to as Luye Pharma, is a prominent biopharmaceutical company headquartered in China (CN). Established in 1997, the company has made significant strides in the pharmaceutical industry, focusing on innovative drug development and manufacturing. With a strong presence in major operational regions including Asia, Europe, and North America, Luye Pharma is dedicated to addressing unmet medical needs across various therapeutic areas. The company’s core products encompass a range of advanced formulations, particularly in oncology, central nervous system disorders, and cardiovascular diseases. Luye Pharma is recognised for its unique drug delivery systems, which enhance the efficacy and patient compliance of its therapies. With a commitment to research and development, Luye Pharma has achieved notable milestones, positioning itself as a key player in the global biopharmaceutical market.
DitchCarbon Score
How does Luye Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Luye Pharma's score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Luye Pharma's reported carbon emissions
In 2023, Luye Pharma reported total carbon emissions of approximately 76,201,350 kg CO2e. This figure includes emissions from both Scope 1 and Scope 2 sources, with Scope 1 emissions accounting for about 2,321,050 kg CO2e from fugitive emissions, 60,520 kg CO2e from mobile combustion, and 8,283,930 kg CO2e from stationary combustion. Scope 2 emissions, primarily from purchased electricity and steam, totalled approximately 46,630,270 kg CO2e and 18,815,810 kg CO2e, respectively. Over the years, Luye Pharma's emissions have fluctuated, with a notable increase from about 51,261,860 kg CO2e in 2018 to 78,081,450 kg CO2e in 2022. However, there was a slight decrease in emissions from 2022 to 2023, indicating a potential shift towards more sustainable practices. Despite these figures, Luye Pharma has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi). Their climate commitments remain unspecified, suggesting an opportunity for the company to enhance its sustainability strategy and set measurable goals for emissions reduction in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 2,284,540 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 42,156,830 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Luye Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
